Reviews/Added Sugar and Metabolic Health/Sugar raises cardiovascular disease risk
Cardiometabolic · ASMH-CMB-02 · v2
Across this corpus, eating more added or free sugar tends to move cardiovascular warning signs in the wrong direction, such as blood fats, uric acid and markers of dyslipidemia. A controlled feeding study that raised sugar in steps [2] and a large population study [12] both point that way, and studies that cut sugar [8] or improved diet quality [7] show the markers improve. But the two cleanest trials that deliberately added sugar against a control [1][4] found no real change, and a small trial in teenage boys [3] did not reach a significant between-group result. Just as important, not one study here follows people to an actual heart attack, stroke or death; every result is an intermediate blood or body measurement. So the evidence speaks to risk factors rather than to cardiovascular disease itself, which is why the panel did not treat the claim as settled.
The signal is positive but uneven at the risk-factor level. A dose-response feeding study showed beverages providing 10%, 17.5% or 25% of energy from high-fructose corn syrup produced linear increases in lipid/lipoprotein CVD risk factors and uric acid within 2 weeks [2]. A cohort found the risk of dyslipidemia increased by 38% with >20 g/d free sugar intake (HR = 1.38, 95% CI: 1.04-1.84) versus <5 g/d [12]. Reducing sugar-sweetened beverage intake correlated with improved HOMA-IR (r = 0.16; P = .03) and reduced waist circumference [8], and improving carbohydrate quality tracked favourable risk-factor changes [7]. Against this, an SSB-versus-alternatives trial found the triglyceride to HDL ratio unchanged between groups over 12 months [1], and an added-versus-fruit-sugar trial found no cardiometabolic change except uric acid [4]. The contested point: The division is between experimental and observational support for worse risk factors [2][12][8][7] and the two cleanest randomised added-sugar interventions returning null results [1][4], with [3]'s between-group difference non-significant (P=0.08). Underlying all of it, no included paper measures a hard cardiovascular event or death, so the corpus cannot carry the claim past surrogate markers.
All 12 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Added Sugar and Metabolic Health, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No included paper measures a hard cardiovascular endpoint (event or mortality); every endpoint is a surrogate risk factor (lipids, uric acid, HOMA-IR, waist circumference, dyslipidemia, composite CVH score). The claim's 'cardiovascular disease risk' is supported only at the intermediate-marker level, a material indirectness gap.
The two cleanest randomised added-sugar interventions are null: [1] found TG:HDL unchanged between groups over 12 months and [4] found no cardiometabolic change except uric acid. Direct experimental causation from added sugar to adverse cardiovascular markers is not demonstrated.
Where it remains uncertain. The two cleanest randomised added-sugar interventions were null [1][4], and every endpoint in the corpus is a surrogate rather than a cardiovascular event or death.
Aleatory
Several interventions are small (N=40 in [3], N=41 in [4]), so chance variation can swamp a true effect and widen confidence intervals.
Epistemic
No included paper measures a cardiovascular event or mortality; the link from markers to disease is assumed, not observed here.
Inferential
Reading lipid, uric acid, HOMA-IR, waist and dyslipidemia changes as 'cardiovascular disease risk' assumes these markers reliably predict events.
The load-bearing papers from a corpus of 12, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Counter-evidence: a 12-month RCT found no difference in the primary cardiometabolic outcome between sugar-sweetened and non-caloric beverages.
“Change in serum triglyceride to high-density lipoprotein cholesterol ratio was not different between groups.”
Panel auditInternal validity: high · scope of inference: Adults habitually consuming SSBs, over 12 months, measured on intermediate cardiometabolic markers and body weight.Key limitations: surrogate markers not CVD events · subgroup weight effect only in high-trunk-fat tertile · beverage substitution not sugar dose per se
Strongest experimental support: a dose-dependent rise in CVD risk factors with increasing added-sugar intake.
“These results provide mechanistic support for the epidemiologic evidence that the risk of cardiovascular mortality is positively associated with consumption of increasing amounts of added sugars.”
Panel auditInternal validity: medium · scope of inference: Young/middle adults (18-40y, BMI 18-35), 2-week exposure, intermediate lipid/lipoprotein risk factors.Key limitations: nonrandomized allocation · 2-week duration · risk factors not clinical CVD · HFCS beverages specifically
Mixed: free-sugar restriction improved cardiovascular health within-group but not significantly versus usual diet.
“After 8 weeks, the mean changes in CVH scores for the free-sugar diet were not significantly different from those of the usual diet (MD=4.98, 95% CI, 0.6, 10.6; P=0.08).”
Panel auditInternal validity: medium · scope of inference: Adolescent boys (11-16y, 95% Latinx) with MASLD over 8 weeks, composite CVH score.Key limitations: n=40, underpowered · open-label · composite CVH surrogate · between-group effect non-significant
3 of 12 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus carries the direction of effect on intermediate cardiovascular risk factors but cannot reach demonstrated CVD disease risk, and mixed RCT evidence keeps confidence in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No hard cardiovascular outcome. The claim names 'cardiovascular disease risk' but the corpus measures only intermediate markers, so disease risk is never demonstrated. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-term cohort or pragmatic trial powered on incident cardiovascular events or mortality as a function of quantified added-sugar intake.
Open question: Does high added sugar intake increase incident cardiovascular events or mortality, not just risk markers? Why it is still open: No included paper measures a cardiovascular event or death; all endpoints are surrogate markers.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19